Answers are grounded in this paper and cite their sources.
The DNA/RNA binding protein TARDBP or TDP-43 is a key driver of pathology in Amyotrophic Lateral Sclerosis (ALS), a motor neuron disease with no known cure. In >97% of sporadic ALS patients, nuclear TDP-43 in motor neurons mislocalizes and aggregates in the cellular cytoplasm (gain-of-function). A parallel reduction in nuclear TDP-43 in ALS patients leads to a loss-of-function in mRNA binding and splicing regulation. Using our machine learning platform, we discovered ACE-339, a novel, orally bioavailable small molecule that disrupts insoluble TDP-43 aggregates. Using in vitro, in vivo and in silico models, we show that ACE-339 directly targets aggregated forms of TDP-43. ACE-339 interacts directly with TDP-43 hexamers, disaggregates recombinant TDP-43 and rescues both gain- and loss-of-function phenotypes of TDP-43 in cells. ACE-339 functionally rescues TDP-43 dependent mis-splicing and synaptic activity. Lastly, ACE-339 rescues disease associated phenotypes in two independent mouse models of TDP-43 pathology. In addition, we now have a catalog of TDP-43 disaggregating compounds that are being developed further to be tested in clinical trials in patients with ALS and other TDP-43 proteinopathies.
No takes yet. Share an insight, caveat, or question.
Kokes et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: